Abstract
α-Synuclein is a major component of Lewy bodies in Parkinsons disease and is found associated with several other forms of dementia. As with other neurodegenerative diseases, the ability of α-synuclein to aggregate and form fibrillar deposits seems central to its pathology. We have defined a sequence within the NAC region of α-synuclein that is necessary for aggregation. Exploitation of chemically modified analogues of this peptide may produce inhibitors of aggregation.
Keywords: synuclein, amyloid, aggregation, parkinsons disease
Protein & Peptide Letters
Title: α-Synuclein Aggregation
Volume: 11 Issue: 3
Author(s): Angela M. Bodles and G. Brent Irvine
Affiliation:
Keywords: synuclein, amyloid, aggregation, parkinsons disease
Abstract: α-Synuclein is a major component of Lewy bodies in Parkinsons disease and is found associated with several other forms of dementia. As with other neurodegenerative diseases, the ability of α-synuclein to aggregate and form fibrillar deposits seems central to its pathology. We have defined a sequence within the NAC region of α-synuclein that is necessary for aggregation. Exploitation of chemically modified analogues of this peptide may produce inhibitors of aggregation.
Export Options
About this article
Cite this article as:
Bodles M. Angela and Irvine Brent G., α-Synuclein Aggregation, Protein & Peptide Letters 2004; 11 (3) . https://dx.doi.org/10.2174/0929866043407084
DOI https://dx.doi.org/10.2174/0929866043407084 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic:Sleep Medicine (Guest Editor: Salim Surani)]
Current Respiratory Medicine Reviews Autoantibodies Profile in Matching CSF and Serum from AD and aMCI patients: Potential Pathogenic Role and Link to Oxidative Damage
Current Alzheimer Research The Metabolic Syndrome and HIV Infection
Current Pharmaceutical Design Blood Coagulation and the Risk of Atherothrombosis
Current Genomics A Common Biological Mechanism in Cancer and Alzheimers Disease?
Current Alzheimer Research Apolipoprotein E Knockout Models
Current Pharmaceutical Design Characterization of the Effect of a Novel γ-secretase Modulator on Aβ: A Clinically Translatable Model
Current Pharmaceutical Design AMPA Receptor Potentiators: Application for Depression and Parkinsons Disease
Current Drug Targets The Role of Autophagy on the Survival of Dopamine Neurons
Current Topics in Medicinal Chemistry Protective Effects of Isothiocyanates against Alzheimer's Disease
Current Traditional Medicine Functional Connectivity in a Rat Model of Alzheimer's Disease During a Working Memory Task
Current Alzheimer Research Current and Future Therapeutic Strategies for Parkinsons Disease
Current Pharmaceutical Design Transition of Care for Patients with Diabetes
Current Diabetes Reviews Significant Overlapping Modules and Biological Processes Between Stroke and Coronary Heart Disease
CNS & Neurological Disorders - Drug Targets Exploring the Role of Aggregated Proteomes in the Pathogenesis of Alzheimer’s Disease
Current Protein & Peptide Science Immunotherapy in a Rabbit Model of Alzheimer’s Disease
Drug Delivery Letters In Vitro Models of the Blood-Brain Barrier: When to Use Which?
Current Medicinal Chemistry - Central Nervous System Agents Targeting Neurotrophic Signal Transduction Pathways in the Treatment of Mood Disorders
Current Signal Transduction Therapy Meet Our Editorial Board Member:
Current Drug Safety Solid Lipid Nanoparticles and Nanostructured Lipid Carriers: A Review
Current Drug Therapy